Home

Marco Polo Bir kenara söyle Karamsar lancet oncology impact factor Kapalı şerit etiket buruşuk

The Lancet Oncology
The Lancet Oncology

The Lancet Oncology | Journal | ScienceDirect.com by Elsevier
The Lancet Oncology | Journal | ScienceDirect.com by Elsevier

The Lancet Oncology, October 2011, Volume 12, Issue 11, Pages 981-1080
The Lancet Oncology, October 2011, Volume 12, Issue 11, Pages 981-1080

Changes in cancer diagnoses and stage distribution during the first year of  the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment -  The Lancet Oncology
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment - The Lancet Oncology

The Lancet more than doubles its impact factor, eclipsing NEJM for the  first time ever – Retraction Watch
The Lancet more than doubles its impact factor, eclipsing NEJM for the first time ever – Retraction Watch

Global characteristics and outcomes of SARS-CoV-2 infection in children and  adolescents with cancer (GRCCC): a cohort study - The Lancet Oncology
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study - The Lancet Oncology

The Lancet Oncology | Journal | ScienceDirect.com by Elsevier
The Lancet Oncology | Journal | ScienceDirect.com by Elsevier

The Lancet Group — impact that matters
The Lancet Group — impact that matters

The Lancet Oncology on X: "The September issue of The Lancet Oncology is  now available online - check it out at https://t.co/BNjH0EQNvk  https://t.co/4mrG91uV2k" / X
The Lancet Oncology on X: "The September issue of The Lancet Oncology is now available online - check it out at https://t.co/BNjH0EQNvk https://t.co/4mrG91uV2k" / X

Zanidatamab for HER2-amplified, unresectable, locally advanced or  metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre,  single-arm, phase 2b study - The Lancet Oncology
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study - The Lancet Oncology

The Lancet Regional Health – Americas
The Lancet Regional Health – Americas

The Lancet Regional Health - Europe: Home Page
The Lancet Regional Health - Europe: Home Page

Lancet Oncology, The
Lancet Oncology, The

The Lancet - Wikipedia
The Lancet - Wikipedia

The Lancet Neurology Home Page
The Lancet Neurology Home Page

The Lancet Digital Health
The Lancet Digital Health

Medical imaging and nuclear medicine: a Lancet Oncology Commission - The Lancet  Oncology
Medical imaging and nuclear medicine: a Lancet Oncology Commission - The Lancet Oncology

The Lancet Haematology | Journal | ScienceDirect.com by Elsevier
The Lancet Haematology | Journal | ScienceDirect.com by Elsevier

Oncology - Q1 Journal list | Ali Guner
Oncology - Q1 Journal list | Ali Guner

The Lancet Oncology, December 2016, Volume 17, Issue 12, Pages 1621-1754,  e515-e568
The Lancet Oncology, December 2016, Volume 17, Issue 12, Pages 1621-1754, e515-e568

The Lancet Top-Cited Content
The Lancet Top-Cited Content

Updated 2023) New JCR Impact Factor 2022 – (PDF) – Journal Impact Factor
Updated 2023) New JCR Impact Factor 2022 – (PDF) – Journal Impact Factor

The Lancet Haematology Home Page
The Lancet Haematology Home Page

The Lancet Oncology, May 2022, Volume 23, Issue 5, Pages 553-690, e198-e235
The Lancet Oncology, May 2022, Volume 23, Issue 5, Pages 553-690, e198-e235

Cancer in sub-Saharan Africa: a Lancet Oncology Commission - The Lancet  Oncology
Cancer in sub-Saharan Africa: a Lancet Oncology Commission - The Lancet Oncology

Lancet Regional Health - Europe, The impact factor and... | Exaly
Lancet Regional Health - Europe, The impact factor and... | Exaly

The Lancet Oncology, February 2022, Volume 23, Issue 2, Pages 185-316,  e45-e88
The Lancet Oncology, February 2022, Volume 23, Issue 2, Pages 185-316, e45-e88